NasdaqGM:IIN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has IntriCon's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IIN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.8%

IIN

-1.1%

US Medical Equipment

-1.4%

US Market


1 Year Return

-30.6%

IIN

23.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: IIN underperformed the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: IIN underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

IINIndustryMarket
7 Day-2.8%-1.1%-1.4%
30 Day11.3%5.2%4.7%
90 Day15.0%6.7%8.2%
1 Year-30.6%-30.6%24.8%23.8%20.5%17.8%
3 Year15.2%15.2%73.9%69.4%42.2%32.7%
5 Year60.6%60.6%145.2%126.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is IntriCon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IntriCon undervalued compared to its fair value and its price relative to the market?

47.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IIN ($13.3) is trading below our estimate of fair value ($25.11)

Significantly Below Fair Value: IIN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IIN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: IIN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IIN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IIN is good value based on its PB Ratio (1.3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is IntriCon forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

119.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: IIN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IIN's is expected to become profitable in the next 3 years.

Revenue vs Market: IIN's revenue (13.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: IIN's revenue (13.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IIN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has IntriCon performed over the past 5 years?

-13.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IIN is currently unprofitable.

Growing Profit Margin: IIN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IIN is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.

Accelerating Growth: Unable to compare IIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IIN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).


Return on Equity

High ROE: IIN has a negative Return on Equity (-4.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is IntriCon's financial position?


Financial Position Analysis

Short Term Liabilities: IIN's short term assets ($68.8M) exceed its short term liabilities ($19.4M).

Long Term Liabilities: IIN's short term assets ($68.8M) exceed its long term liabilities ($8.2M).


Debt to Equity History and Analysis

Debt Level: IIN is debt free.

Reducing Debt: IIN has no debt compared to 5 years ago when its debt to equity ratio was 40.5%.

Debt Coverage: IIN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IIN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is IntriCon current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IIN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IIN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

J. Longval (43 yo)

no data

Tenure

US$439,794

Compensation

Mr. J. Scott Longval has been Chief Executive Officer, President and Director of IntriCon Corporation until October 1, 2020. He served as an Executive Vice President at IntriCon Corporation until September ...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD439.79K) is about average for companies of similar size in the US market ($USD589.00K).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
J. Longval
Presidentno dataUS$439.79k0.43%
$ 513.7k
Michael Geraci
Senior Vice President of Sales & Marketing25.75yrsUS$417.14k0.43%
$ 509.3k
Mark Gorder
Executive Advisory Consultant & Director24.75yrsUS$675.98k3%
$ 3.6m
Dennis Gonsior
Senior Vice President of Global Operations24.75yrsUS$398.77k0.62%
$ 735.9k
Sara Hill
Chief Human Resource Officer0.50yrno datano data
Doug Pletcher
Vice President of Medical Business Development1.75yrsno datano data

1.8yrs

Average Tenure

61yo

Average Age

Experienced Management: IIN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
J. Longval
Presidentno dataUS$439.79k0.43%
$ 513.7k
Mark Gorder
Executive Advisory Consultant & Director24.75yrsUS$675.98k3%
$ 3.6m
Nicholas Giordano
Independent Director19.83yrsUS$146.00k0.95%
$ 1.1m
Raymond Huggenberger
Independent Director1.42yrsUS$108.67kno data
Robert Masucci
Independent Director18.67yrsUS$141.00k0.86%
$ 1.0m
Philip Smith
Independent Chairman of the Board1.42yrsUS$166.33k0.019%
$ 22.6k
Philip Seamon
Director Emeritus3.83yrsUS$104.00kno data
Heather Rider
Director0.58yrno datano data

3.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: IIN's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.


Top Shareholders

Company Information

IntriCon Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IntriCon Corporation
  • Ticker: IIN
  • Exchange: NasdaqGM
  • Founded: 1930
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$118.819m
  • Shares outstanding: 8.93m
  • Website: https://www.intricon.com

Number of Employees


Location

  • IntriCon Corporation
  • 1260 Red Fox Road
  • Arden Hills
  • Minnesota
  • 55112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IINNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1968
SLJDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1968

Biography

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company oper ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:54
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.